Harnessing SARS-CoV-2-specific CD8⁺ T cells to kill target tumor cells for cancer immunotherapy

Cancer Commun (Lond). 2024 Jan;44(1):173-177. doi: 10.1002/cac2.12497. Epub 2023 Oct 19.

Authors

Keunok Jung¹, Deok-Han Ko², Jeong-Yun Jang², Young Rong Kim³, Jung Yeon Heo³, Yong-Sung Kim^{1

2}

Affiliations

¹ Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Republic of Korea.
² Department of Molecular Science and Technology, Ajou University, Suwon, Republic of Korea.
³ Department of Infectious Diseases, Ajou University School of Medicine, Suwon, Republic of Korea.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

CD8-Positive T-Lymphocytes
COVID-19*
Humans
Immunotherapy
Neoplasms* / therapy
SARS-CoV-2

Grants and funding